230 related articles for article (PubMed ID: 9622541)
1. Orally active benzamide antipsychotic agents with affinity for dopamine D2, serotonin 5-HT1A, and adrenergic alpha1 receptors.
Reitz AB; Baxter EW; Codd EE; Davis CB; Jordan AD; Maryanoff BE; Maryanoff CA; McDonnell ME; Powell ET; Renzi MJ; Schott MR; Scott MK; Shank RP; Vaught JL
J Med Chem; 1998 Jun; 41(12):1997-2009. PubMed ID: 9622541
[TBL] [Abstract][Full Text] [Related]
2. Novel benzothiazolin-2-one and benzoxazin-3-one arylpiperazine derivatives with mixed 5HT1A/D2 affinity as potential atypical antipsychotics.
Taverne T; Diouf O; Depreux P; Poupaert JH; Lesieur D; Guardiola-Lemaître B; Renard P; Rettori MC; Caignard DH; Pfeiffer B
J Med Chem; 1998 Jun; 41(12):2010-8. PubMed ID: 9622542
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and structure-activity relationships of a new model of arylpiperazines. 4. 1-[omega-(4-Arylpiperazin-1-yl)alkyl]-3-(diphenylmethylene) - 2, 5-pyrrolidinediones and -3-(9H-fluoren-9-ylidene)-2, 5-pyrrolidinediones: study of the steric requirements of the terminal amide fragment on 5-HT1A affinity/selectivity.
López-Rodríguez ML; Morcillo MJ; Rovat TK; Fernández E; Vicente B; Sanz AM; Hernández M; Orensanz L
J Med Chem; 1999 Jan; 42(1):36-49. PubMed ID: 9888831
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and Pharmacology of the enantiomers of the potential atypical antipsychotic agents 5-OMe-BPAT and 5-OMe-(2,6-di-OMe)-BPAT.
Homan EJ; Copinga S; Unelius L; Jackson DM; Wikström HV; Grol CJ
Bioorg Med Chem; 1999 Jul; 7(7):1263-71. PubMed ID: 10465402
[TBL] [Abstract][Full Text] [Related]
5. New pyridobenzodiazepine derivatives: modifications of the basic side chain differentially modulate binding to dopamine (D(4.2), D(2L)) and serotonin (5-HT(2A)) receptors.
Liégeois JF; Eyrolles L; Ellenbroek BA; Lejeune C; Carato P; Bruhwyler J; Géczy J; Damas J; Delarge J
J Med Chem; 2002 Nov; 45(23):5136-49. PubMed ID: 12408724
[TBL] [Abstract][Full Text] [Related]
6. Conformationally constrained butyrophenones with mixed dopaminergic (D(2)) and serotoninergic (5-HT(2A), 5-HT(2C)) affinities: synthesis, pharmacology, 3D-QSAR, and molecular modeling of (aminoalkyl)benzo- and -thienocycloalkanones as putative atypical antipsychotics.
Raviña E; Negreira J; Cid J; Masaguer CF; Rosa E; Rivas ME; Fontenla JA; Loza MI; Tristán H; Cadavid MI; Sanz F; Lozoya E; Carotti A; Carrieri A
J Med Chem; 1999 Jul; 42(15):2774-97. PubMed ID: 10425088
[TBL] [Abstract][Full Text] [Related]
7. Structure-activity relationships of a series of substituted benzamides: potent D2/5-HT2 antagonists and 5-HT1a agonists as neuroleptic agents.
Norman MH; Rigdon GC; Hall WR; Navas F
J Med Chem; 1996 Mar; 39(5):1172-88. PubMed ID: 8676355
[TBL] [Abstract][Full Text] [Related]
8. 1-Aryl-4-(4-succinimidobutyl)piperazines and their conformationally constrained analogues: synthesis, binding to serotonin (5-HT1A, 5-HT2A, 5-HT7), alpha1-adrenergic, and dopaminergic D2 receptors, and in vivo 5-HT1A functional characteristics.
Bojarski AJ; Paluchowska MH; Duszyńska B; Kłodzińska A; Tatarczyńska E; Chojnacka-Wójcik E
Bioorg Med Chem; 2005 Mar; 13(6):2293-303. PubMed ID: 15727878
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and structure-activity relationships of a new model of arylpiperazines. 1. 2-[[4-(o-methoxyphenyl)piperazin-1-yl]methyl]-1, 3-dioxoperhydroimidazo[1,5-alpha]pyridine: a selective 5-HT1A receptor agonist.
López-Rodríguez ML; Rosado ML; Benhamú B; Morcillo MJ; Sanz AM; Orensanz L; Beneitez ME; Fuentes JA; Manzanares J
J Med Chem; 1996 Oct; 39(22):4439-50. PubMed ID: 8893838
[TBL] [Abstract][Full Text] [Related]
10. 1-aryl-4-[(5-methoxy-1,2,3, 4-tetrahydronaphthalen-1-yl)alkyl]piperazines and their analogues: influence of the stereochemistry of the tetrahydronaphthalen-1-yl nucleus on 5-HT1A receptor affinity and selectivity versus alpha1 and D2 receptors. 5.
Perrone R; Berardi F; Colabufo NA; Leopoldo M; Tortorella V
J Med Chem; 1999 Feb; 42(3):490-6. PubMed ID: 9986719
[TBL] [Abstract][Full Text] [Related]
11. Novel 4-alkyl-1-arylpiperazines and 1,2,3,4-tetrahydroisoquinolines containing diphenylmethylamino or diphenylmethoxy fragment with differentiated 5-HT1A/5-HT2A/D2 receptor activity.
Paluchowska MH; Mokrosz MJ; Charakchieva-Minol S; Duszyńska B; Kozioł A; Wesołowska A; Stachowicz K; Chojnacka-Wójcik E
Pol J Pharmacol; 2003; 55(4):543-52. PubMed ID: 14581712
[TBL] [Abstract][Full Text] [Related]
12. Substituted phenoxyalkylpiperazines as dopamine D3 receptor ligands.
Laszlovszky I; Acs T; Kiss B; Domány G
Pharmazie; 2001 Apr; 56(4):287-9. PubMed ID: 11338664
[TBL] [Abstract][Full Text] [Related]
13. Pyrrolo[1,3]benzothiazepine-based serotonin and dopamine receptor antagonists. Molecular modeling, further structure-activity relationship studies, and identification of novel atypical antipsychotic agents.
Campiani G; Butini S; Fattorusso C; Catalanotti B; Gemma S; Nacci V; Morelli E; Cagnotto A; Mereghetti I; Mennini T; Carli M; Minetti P; Di Cesare MA; Mastroianni D; Scafetta N; Galletti B; Stasi MA; Castorina M; Pacifici L; Vertechy M; Di Serio S; Ghirardi O; Tinti O; Carminati P
J Med Chem; 2004 Jan; 47(1):143-57. PubMed ID: 14695828
[TBL] [Abstract][Full Text] [Related]
14. Introduction of a methyl group in alpha- or beta-position of 1-heteroarylethyl-4-phenylpiperazines affects their dopaminergic/serotonergic properties.
Roglic G; Andric D; Kostic-Rajacic S; Dukic S; Soskic V
Arch Pharm (Weinheim); 2001 Dec; 334(12):375-80. PubMed ID: 11852532
[TBL] [Abstract][Full Text] [Related]
15. New pyridobenzoxazepine derivatives derived from 5-(4-methylpiperazin-1-yl)-8-chloro-pyrido[2,3-b][1,5]benzoxazepine (JL13): chemical synthesis and pharmacological evaluation.
Liégeois JF; Deville M; Dilly S; Lamy C; Mangin F; Résimont M; Tarazi FI
J Med Chem; 2012 Feb; 55(4):1572-82. PubMed ID: 22268448
[TBL] [Abstract][Full Text] [Related]
16. Piperazinylalkyl heterocycles as potential antipsychotic agents.
Scott MK; Baxter EW; Bennett DJ; Boyd RE; Blum PS; Codd EE; Kukla MJ; Malloy E; Maryanoff BE; Maryanoff CA
J Med Chem; 1995 Oct; 38(21):4198-210. PubMed ID: 7473547
[TBL] [Abstract][Full Text] [Related]
17. Aminopyrimidines with high affinity for both serotonin and dopamine receptors.
Wustrow D; Belliotti T; Glase S; Kesten SR; Johnson D; Colbry N; Rubin R; Blackburn A; Akunne H; Corbin A; Davis MD; Georgic L; Whetzel S; Zoski K; Heffner T; Pugsley T; Wise L
J Med Chem; 1998 Feb; 41(5):760-71. PubMed ID: 9513604
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological profiles in rats of novel antipsychotics with combined dopamine D2/serotonin 5-HT1A activity: comparison with typical and atypical conventional antipsychotics.
Bardin L; Auclair A; Kleven MS; Prinssen EP; Koek W; Newman-Tancredi A; Depoortère R
Behav Pharmacol; 2007 Mar; 18(2):103-18. PubMed ID: 17351418
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and in vitro pharmacological evaluation of a new series of 5-HT1A 5-HT2A and 5-HT2C receptor ligands containing a norbornene nucleus.
Fiorino F; Severino B; De Angelis F; Perissutti E; Magli E; Frecentese F; Esposito A; Massarelli P; Nencini C; Viti B; Santagada V; Caliendo G
Pharmazie; 2009 Sep; 64(9):555-64. PubMed ID: 19827295
[TBL] [Abstract][Full Text] [Related]
20. N-aryl-N'-benzylpiperazines as potential antipsychotic agents.
Reitz AB; Baxter EW; Bennett DJ; Codd EE; Jordan AD; Malloy EA; Maryanoff BE; McDonnell ME; Ortegon ME; Renzi MJ
J Med Chem; 1995 Oct; 38(21):4211-22. PubMed ID: 7473548
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
